Skip Navigation

European Heart Journal 1991 12(12):1283-1287;
Copyright © 1991 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by FOX, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FOX, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 The European Society of Cardiology

The effects of nisoldipine on the total ischaemic burden: the results of the ROCKET study

K. FOX*,, J. POOL{dagger}, $$$ VOS{dagger}, J. LUBSEN{dagger} and ON BEHALF OF THE ROCKET-STUDY GROUP

*Royal Brompton and National Heart Hospital Westmoreland Street, London W1M 8BA
{dagger}Thoraxcentrum, Erasmus University 3000 DR Rotterdam

Received 6 July 1990; revised 1 November 1990; .

Correspondence: Kim Fox, Royal Brompton and National Heart Hospital, Sydney Street, London SW3

Abstract

This study was designed to examine the effects of nisoldipine (relative to placebo), a new dihydropyridine calcium entry blocking agent, in the treatment of silent ischaemia in conventional doses.

A total of 409 patients with proven coronary artery disease were screened and of this 64 had at least six episodes or a total duration of 30 mm of ST segment depression (1 mm lasting at least 1 min) over 48 h. Fifty-two patients ultimately completed a randomized double-blind cross-over study comparing nisoldipine 5 mg twice a day, nisoldipine 10 mg daily and placebo.

There was a reduction in the ST segment integral and number of episodes of ST segment depression when compared to placebo on treatment with nisoldipine 5 mg twice a day and nisoldipine 10 mg daily. However, the confidence limits were wide and crossed the no-treatment effect line. In addition, the nisoldipine doses neither affected the circadian distribution of ischaemic episodes nor caused an alteration of the workload achieved either at peak exercise or at 1 mm ST segment depression measured 24 h after nidoldipine 10 mg or 12 h after nisoldipine 5 mg.

We conclude that frequent silent ischaemia in patients with proven coronary artery disease is relatively uncommon, it accounts for approximately 16% of patients with positive exercise. In these patients nisoldipine, given as 5mg twice a day and 10 mg daily, showed no significant therapeutic effects, either on the frequency or severity of silent ischaemia. New formulations of slow release nisoldipine are consequently being developed so that a fuller 24 h therapeutic profile may be obtained.

Key Words: Silent ischaemia • calcium antagonist • angina pectoris


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.